Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11141-SE

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11141-SE-020
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Conjugate

Unconjugated

Applications

Enzyme Activity

View all DPPIV/CD26 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human DPPIV/CD26 protein
Human CD26
(Asn29-Pro766)
Accession # CAA43118.1		 DIEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Asn29

Predicted Molecular Mass

112 kDa

SDS-PAGE

116-131 kDa, under reducing conditions

Activity

Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC).
The specific activity is >3000 pmol/min/μg, as measured under the described conditions.

Scientific Data Images for Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF

Recombinant Human DPPIV/CD26 Fc Chimera Protein Enzyme Activity.

Recombinant Human DPPIV/CD26 Fc Chimera (Catalog # 11141-SE) is measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC).

Recombinant Human DPPIV/CD26 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Human DPPIV/CD26 Fc Chimera Protein (Catalog # 11141-SE) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 116-131 kDa and 230-260 kDa, respectively.

Formulation, Preparation and Storage

11141-SE
Formulation Supplied as a 0.2 μm filtered solution in Tris and NaCl.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: DPPIV/CD26

Dipeptidyl peptidase 4 (DPPIV, also known as CD26) is an approximately 110 kDa serine exopeptidase that releases Xaa-Pro or Xaa-Ala dipeptides from the N-terminus of oligo- and polypeptides. Mature human DPPIV consists of a 6 amino acid (aa) cytoplasmic tail, a 22 aa transmembrane segment, and a 738 aa extracellular domain (ECD) that contains the catalytic active site (1). DPPIV is expressed as a noncovalent homodimer on the surface of epithelial cells, endothelial cells, and activated lymphocytes, and it can be released by MMP mediated shedding (2). It regulates immune and endocrine function through the cleavage of multiple chemokines, growth factors, and peptide hormones (3,4). It cleaves a range of peptide hormones including Glucagon, Glucagon-like Peptides 1 and 2, GIP, GHRH, Procalcitonin, Neuropeptide Y, and Substance P (5). It is released from adipocytes and induces insulin resistance in adipocytes and skeletal muscle (6). DPPIV also cleaves many chemokines, resulting in altered chemotactic activity (7-10) or impacting chemokine blockade of HIV-1 cellular infectivity depending on the chemokine target (7,9,11). It cleaves human GM-CSF and IL-3 and reduces their ability to promote myeloid cell development (12). In addition to enzymatic cleavage functions, DPPIV interacts with adenosine deaminase on T cells and with caveolin-1 on antigen presenting cells (13), provides costimulatory proliferation and activation signals to both CD4+ and CD8+ T cells (13,14), and serves as a cell entry coreceptor for HIV and coronavirus MERS-CoV-2 (15,16). DPPIV inhibitors are approved for therapeutic treatment in type 2 diabetes (17) and are being explored for treatment of several additional conditions including autoimmune diseases (18).

References

  1. Tanaka, T. et al. (1992) J. Immunol. 149:481.
  2. Rohrborn, D. et al. (2014) FEBS Lett. 588:3870.
  3. Klemann, C. et al. (2016) Clin. Exp. Immunol. 185:1.
  4. Mortier, A. et al. (2016) J. Leukoc. Biol. 99:955.
  5. Waumans, Y. et al. (2015) Front. Immunol. 6:387.
  6. Lamers, D. et al. (2011) Diabetes 60:1917.
  7. Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
  8. Proost, P. et al. (2001) Blood 98:3554.
  9. Ohtsuki, T. et al. (1998) FEBS Lett. 431:236.
  10. Barreira da Silva, R. et al. (2015) Nat. Immunol. 16:850.
  11. Guan, E. et al. (2002) J. Biol. Chem. 277:32348.
  12. Broxmeyer, H.E. et al. (2012) Nat. Med. 18:1786.
  13. Ohnuma, K. et al. (2007) J. Biol. Chem. 282:10117.
  14. Hatano, R. et al. (2013) Immunology 138:165.
  15. Callebaut, C. et al. (1993) Science 262:2045.
  16. Raj, V.S. et al. (2013) Nature 495:251.
  17. Makrilakis, K. (2019) Int. J. Environ. Res. Public Health 16:2720.
  18. Huang, J. et al. (2022) Front. Immunol. 13:830863.

Long Name

Dipeptidyl-peptidase IV

Alternate Names

CD26, DPP4

Entrez Gene IDs

1803 (Human); 13482 (Mouse); 397492 (Porcine); 102133935 (Cynomolgus Monkey)

Gene Symbol

DPP4

Additional DPPIV/CD26 Products

Product Documents for Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.